Exousia Bio (LMMY) EBITDA Margin (2023 - 2024)
Exousia Bio (LMMY) posted EBITDA Margin of 17.76% for Q3 2024, down 106.14% sequentially from 289.04% in Q2 2024.
Powered by 
Analysis
Exousia Bio (LMMY) EBITDA Margin (2023 - 2024) Analysis & Trends
Exousia Bio (LMMY) has 2 years of EBITDA Margin data on file, last reported at 17.76% in Q3 2024.
- Quarterly EBITDA Margin changed N/A year-over-year to 17.76% in Q3 2024, while the trailing twelve-month figure through May 2025 was 72.35% (up 24542.0% YoY) and the FY2025 annual result came in at 465.73%, down 31386.0% from the prior year.
- EBITDA Margin declined to 17.76% in Q3 2024 per LMMY's latest filing, from 289.04% in the prior quarter.
- The five-year high for EBITDA Margin was 289.04% in Q2 2024, with the low at 224.39% in Q1 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | New Oriental Education & Technology | 94.85 Bn | 92.11 Bn | 812.22 Mn | 5.61% |
| 2 | Laureate Education | 5.09 Bn | 4.93 Bn | 237.67 Mn | 36.28% |
| 3 | Graham Holdings | 4.81 Bn | 3.57 Bn | 777.03 Mn | 7.82% |
| 4 | Covista | 4.54 Bn | 4.14 Bn | 284.63 Mn | 19.04% |
| 5 | Grand Canyon Education | 4.00 Bn | 3.72 Bn | 204.08 Mn | 22.02% |
| 6 | Stride | 3.70 Bn | 2.74 Bn | 217.28 Mn | 16.64% |
| 7 | McGraw Hill | 2.54 Bn | 2.35 Bn | 439.20 Mn | 23.76% |
| 8 | Perdoceo Education | 2.10 Bn | 792.68 Mn | 162.46 Mn | 25.72% |
| 9 | TAL Education | 1.94 Bn | -742.06 Mn | 227.32 Mn | -10.34% |
| 10 | Exousia Bio | 368,824.87 | 368,824.87 | -62,108.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Aug 31, 2024 | -17.76% |
| May 31, 2024 | -151.71% |
| Feb 29, 2024 | -224.39% |
| Nov 30, 2023 | -192.21% |